The acquisition enhances the portfolio of Aditxt in precision diagnostics and infectious disease treatment. Credit: Gorodenkoff / Shutterstock.com.
Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common shares of biopharmaceutical company Appili Therapeutics.
The move enhances Aditxt’s portfolio and creates synergies with its existing programmes, particularly in precision diagnostics.
LIKMEZ is a reformulated version of the antibiotic metronidazole that improves patient experience and compliance by making the medication easier to swallow and better tasting.
Appili licensed the manufacturing and commercialisation rights of the product in the US and other selected territories to Saptalis Pharmaceuticals.
The product, which contains paromomycin, offers a more patient-friendly treatment option for this painful and disfiguring disease.
The acquisition will aid Aditxt in bolstering its portfolio and integrating precision diagnostics with tailored treatment strategies.
The closure of the acquisition will occur in the third quarter of 2024.
Aditxt co-founder, chairman and CEO Amro Albanna stated: “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health.
“Our mission is to accelerate some of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact.
“By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefence domain, Aditxt can substantially contribute to advancing public health solutions.”